End Stage Renal Disease (ESRD) Drug Global Market Report 2024

Description

“End Stage Renal Disease (ESRD) Drug Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on end stage renal disease (esrd) drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for end stage renal disease (esrd) drug? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The end stage renal disease (esrd) drug market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Product Type: Calcimimetics; Vitamin D; Sterols; Potassium Binders; Calcium-Based Phosphate Binders; Other Products
2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism; End Stage Renal Disease (ESRD) Induced Hyperphosphatemia; End Stage Renal Disease (ESRD) Induced Hyperkaliemia
3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
Companies Mentioned: Pfizer Inc.; AstraZeneca plc; Sanofi SA; Astellas Pharma Inc.; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

End Stage Renal Disease (ESRD) drugs are medications employed in the treatment of a medical condition wherein a person's kidneys permanently cease to function, necessitating either a kidney transplant or a regular and long-term dialysis regimen to sustain life. These drugs play a crucial role in addressing and preventing secondary complications in individuals suffering from chronic renal disease (CKD).

The main categories of End Stage Renal Disease (ESRD) drugs include calcimimetics, vitamin D, sterols, potassium binders, calcium-based phosphate binders, and others. Calcimimetics are used to reduce parathyroid hormone (PTH) levels in kidney disease stage 5D, with their application dependent on serum calcium and phosphorus levels. Various indications for these drugs include ESRD-induced hyperparathyroidism, hyperphosphatemia, and hyperkalemia. End Stage Renal Disease drugs are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, catering to usage in hospitals, homecare settings, specialty clinics, and other end-user environments.

The end stage renal disease (ESRD) drug market research report is one of a series of new reports from The Business Research Company that provides end stage renal disease (ESRD) drug market statistics, including end stage renal disease (ESRD) drug industry global market size, regional shares, competitors with an end stage renal disease (ESRD) drug market share, detailed end stage renal disease (ESRD) drug market segments, market trends and opportunities, and any further data you may need to thrive in the end stage renal disease (ESRD) drug industry. This end stage renal disease (ESRD) drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The end stage renal disease (esrd) drug market size has grown rapidly in recent years. It will grow from $116.32 billion in 2023 to $132.86 billion in 2024 at a compound annual growth rate (CAGR) of 14.2%. The growth observed in the historical period can be attributed to several factors, including the increasing incidence of end-stage renal disease (ESRD), a growing aging population, improved access to healthcare services, government initiatives and policies supporting renal health, and an increasing adoption of renal replacement therapies. These factors collectively contributed to the expansion of the market for drugs and treatments related to end-stage renal disease during the historic period.

The end stage renal disease (esrd) drug market size is expected to see rapid growth in the next few years. It will grow to $232.13 billion in 2028 at a compound annual growth rate (CAGR) of 15.0%. The anticipated growth in the forecast period can be attributed to factors such as the emergence of new therapies and drug innovations, a continuous increase in healthcare expenditure, a rising global burden of chronic kidney diseases, the adoption of personalized medicine approaches, and regulatory support leading to expedited approvals. Major trends expected in this period include the increasing incidence of end-stage renal disease, advancements in treatment modalities, a growing emphasis on precision medicine, the development of combination therapies, and increased technological integration in healthcare practices. These trends collectively contribute to the positive outlook for the market for drugs and treatments related to end-stage renal disease in the forecast period.

The anticipated rise in obesity and diabetes cases is projected to be a significant driving force behind the growth of the end-stage renal disease (ESRD) drug market. Obesity, characterized by an abnormal or excessive accumulation of body fat, and diabetes, a chronic condition affecting insulin production or utilization, contribute to renal diseases. Managing fluid and electrolyte levels, blood pressure, and waste elimination through treatments such as dialysis can enhance overall health, potentially leading to weight reduction and improved blood sugar control. As reported by World Obesity in March 2022, the projected increase in obese individuals is estimated to reach 892 million by 2025 and escalate to 1,025 million by 2030. Additionally, the International Diabetes Federation (IDF) highlighted in September 2021 that approximately 537 million individuals aged 20 to 79 were living with diabetes in 2021, with projections indicating an increase to 643 million by 2030 and 783 million by 2045. Hence, the mounting cases of obesity and diabetes are poised to drive the demand for end-stage renal disease (ESRD) drugs.

The escalating prevalence of hypertension is another factor expected to propel the expansion of the end-stage renal disease (ESRD) drug market. Hypertension, characterized by consistently high blood pressure against artery walls, significantly impacts renal health. ESRD drugs play a crucial role in treating hypertension by regulating blood pressure, reducing cardiovascular risk, slowing disease progression, and enhancing fluid balance and quality of life. For example, according to the Centers for Disease Control and Prevention (CDC) in July 2023, hypertension accounted for 691,095 fatalities in the US in 2021. Consequently, the increasing prevalence of hypertension serves as a driving force behind the growth of the end-stage renal disease (ESRD) drug market.

Innovative product development emerges as a prominent trend shaping the end-stage renal disease (ESRD) drug market landscape. Leading companies within this sector are prioritizing the development of innovative solutions to bolster their market positions. A notable instance occurred in April 2022 when GlaxoSmithKline Plc, a UK-based pharmaceutical and biotechnology firm, announced the acceptance of the New Drug Application (NDA) for daprodustat by the US Food and Drug Administration (FDA). Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), is aimed at potentially treating chronic kidney disease anaemia (CKD). This product is founded on groundbreaking science that elucidated cellular oxygen sensing and adaptation, marking a milestone in novel therapeutic approaches within the ESRD drug market.

Prominent companies in the end-stage renal disease (ESRD) drug market are strategically focusing on securing product approvals, exemplified by Jardiance, to augment their market revenues. Jardiance, featuring empagliflozin, is tailored to aid individuals diagnosed with type 2 diabetes and reduce the risk of cardiovascular complications in those with type 2 diabetes experiencing heart failure or cardiovascular disease. A significant development occurred in September 2023 when Boehringer Ingelheim Pharmaceuticals Inc., a US-based pharmaceutical company, obtained FDA approval for Jardiance. This drug has received approval for various indications, including reducing the risk of end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease prone to progression. Additionally, it aims to diminish the risk of sustained decline in estimated glomerular filtration rate (eGFR) in adults suffering from heart failure. Notably, Jardiance operates as a sodium-glucose cotransporter 2 (SGLT2) inhibitor, with contraindications for patients with type 1 diabetes and those exhibiting an eGFR lower than 20 ml/min/1.73 m.

In November 2021, Vifor Pharma, a Switzerland-based pharmaceutical company, acquired Sanifit Therapeutics S.A. for an undisclosed sum. This strategic acquisition served to broaden Vifor Pharma's portfolio by integrating cutting-edge assets. Sanifit Therapeutics S.A., headquartered in Spain, operates as a clinical-stage cardio-renal biopharmaceutical company specializing in developing therapies catering to individuals affected by end-stage kidney diseases. This acquisition marks a strategic expansion for Vifor Pharma, enhancing its expertise and offerings in addressing critical needs within the realm of end-stage renal diseases.

Major companies operating in the end stage renal disease (esrd) drug market report are Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Cantel Medical Corp., Nikkiso Co. Ltd., Abbott Laboratories, Alere Inc., Siemens Healthcare AG, Roche Diagnostics Corporation, Beckman Coulter Inc., Becton Dickinson And Co., Thermo Fisher Scientific Inc., BioMerieux SA, Bio-Rad Laboratories, Randox Laboratories, Enzo Biochem Inc., Merck Co. & KGaA, QIAGEN N.V., PerkinElmer Inc., Tosoh Corporation, Eurolyser Diagnostica GmbH .

North America was the largest region in the end stage renal disease (ESRD) drug market in 2023. The regions covered in the end stage renal disease (esrd) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the end stage renal disease (esrd) drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The end-stage renal disease (ESRD) drug market consists of sales of cinacalcet hcl, diuretics, sevelamer, epoetin alfa, and over-the-counter drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r10927

1. Executive Summary

2. End Stage Renal Disease (ESRD) Drug Market Characteristics

3. End Stage Renal Disease (ESRD) Drug Market Trends And Strategies

4. End Stage Renal Disease (ESRD) Drug Market - Macro Economic Scenario

4.1. Impact Of High Inflation On the Market
4.2. Ukraine-Russia War Impact On the Market
4.3. COVID-19 Impact On the Market

5. Global End Stage Renal Disease (ESRD) Drug Market Size and Growth

5.1. Global End Stage Renal Disease (ESRD) Drug Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global End Stage Renal Disease (ESRD) Drug Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global End Stage Renal Disease (ESRD) Drug Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. End Stage Renal Disease (ESRD) Drug Market Segmentation

6.1. Global End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Calcimimetics
Vitamin D
Sterols
Potassium Binders
Calcium-Based Phosphate Binders
Other Products
6.2. Global End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
End Stage Renal Disease (ESRD) Induced Hyperparathyroidism
End Stage Renal Disease (ESRD) Induced Hyperphosphatemia
End Stage Renal Disease (ESRD) Induced Hyperkalaemia
6.3. Global End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
6.4. Global End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Homecare
Specialty Clinics
Other End Users

7. End Stage Renal Disease (ESRD) Drug Market Regional And Country Analysis

7.1. Global End Stage Renal Disease (ESRD) Drug Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global End Stage Renal Disease (ESRD) Drug Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific End Stage Renal Disease (ESRD) Drug Market

8.1. Asia-Pacific End Stage Renal Disease (ESRD) Drug Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China End Stage Renal Disease (ESRD) Drug Market

9.1. China End Stage Renal Disease (ESRD) Drug Market Overview
9.2. China End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India End Stage Renal Disease (ESRD) Drug Market

10.1. India End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan End Stage Renal Disease (ESRD) Drug Market

11.1. Japan End Stage Renal Disease (ESRD) Drug Market Overview
11.2. Japan End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia End Stage Renal Disease (ESRD) Drug Market

12.1. Australia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia End Stage Renal Disease (ESRD) Drug Market

13.1. Indonesia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea End Stage Renal Disease (ESRD) Drug Market

14.1. South Korea End Stage Renal Disease (ESRD) Drug Market Overview
14.2. South Korea End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe End Stage Renal Disease (ESRD) Drug Market

15.1. Western Europe End Stage Renal Disease (ESRD) Drug Market Overview
15.2. Western Europe End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK End Stage Renal Disease (ESRD) Drug Market

16.1. UK End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany End Stage Renal Disease (ESRD) Drug Market

17.1. Germany End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France End Stage Renal Disease (ESRD) Drug Market

18.1. France End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy End Stage Renal Disease (ESRD) Drug Market

19.1. Italy End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain End Stage Renal Disease (ESRD) Drug Market

20.1. Spain End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe End Stage Renal Disease (ESRD) Drug Market

21.1. Eastern Europe End Stage Renal Disease (ESRD) Drug Market Overview
21.2. Eastern Europe End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia End Stage Renal Disease (ESRD) Drug Market

22.1. Russia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America End Stage Renal Disease (ESRD) Drug Market

23.1. North America End Stage Renal Disease (ESRD) Drug Market Overview
23.2. North America End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA End Stage Renal Disease (ESRD) Drug Market

24.1. USA End Stage Renal Disease (ESRD) Drug Market Overview
24.2. USA End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada End Stage Renal Disease (ESRD) Drug Market

25.1. Canada End Stage Renal Disease (ESRD) Drug Market Overview
25.2. Canada End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America End Stage Renal Disease (ESRD) Drug Market

26.1. South America End Stage Renal Disease (ESRD) Drug Market Overview
26.2. South America End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil End Stage Renal Disease (ESRD) Drug Market

27.1. Brazil End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East End Stage Renal Disease (ESRD) Drug Market

28.1. Middle East End Stage Renal Disease (ESRD) Drug Market Overview
28.2. Middle East End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa End Stage Renal Disease (ESRD) Drug Market

29.1. Africa End Stage Renal Disease (ESRD) Drug Market Overview
29.2. Africa End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. End Stage Renal Disease (ESRD) Drug Market Competitive Landscape And Company Profiles

30.1. End Stage Renal Disease (ESRD) Drug Market Competitive Landscape
30.2. End Stage Renal Disease (ESRD) Drug Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. AstraZeneca plc
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Sanofi SA
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Astellas Pharma Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Novartis AG
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Global End Stage Renal Disease (ESRD) Drug Market Competitive Benchmarking

32. Global End Stage Renal Disease (ESRD) Drug Market Competitive Dashboard

33. Key Mergers And Acquisitions In The End Stage Renal Disease (ESRD) Drug Market

34. End Stage Renal Disease (ESRD) Drug Market Future Outlook and Potential Analysis

34.1 End Stage Renal Disease (ESRD) Drug Market In 2028 - Countries Offering Most New Opportunities
34.2 End Stage Renal Disease (ESRD) Drug Market In 2028 - Segments Offering Most New Opportunities
34.3 End Stage Renal Disease (ESRD) Drug Market In 2028 - Growth Strategies
- 34.3.1 Market Trend Based Strategies
- 34.3.2 Competitor Strategies

35. Appendix

35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer